Leronlimab

• CAT Number: I041590
• CAS Number: 674782-26-4
• Purity: ≥95%

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1].
Leronlimab (1-140 mg/mL) binds to CCR5-positive cells up to 98%[1].
Leronlimab (80-1750 μg/mL) blocks CCL5, CCL3, and CCL4-induced calcium responses in MDA-MB-231-CCR5 cells[1].
Leronlimab (175 and 350 mg/mL) blocks MDA-MB-231 cell invasion[1].
Leronlimab (10 μg/mL; 72 hours) enhances the cytotoxicity of doxorubicin for MDA-MB-231 cells[1].
Leronlimab (2 mg; i.p., twice a week) reduces lung metastasis in murine xenograft models[1].

Reference

[1]. Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11.
 [Content Brief]